These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 26940286)

  • 1. Safety profile of anakinra in the management of rheumatologic, metabolic and autoinflammatory disorders.
    Lopalco G; Rigante D; Giannini M; Galeazzi M; Lapadula G; Iannone F; Cantarini L
    Clin Exp Rheumatol; 2016; 34(3):531-8. PubMed ID: 26940286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders.
    Arnold DD; Yalamanoglu A; Boyman O
    Front Immunol; 2022; 13():888392. PubMed ID: 35874710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blocking interleukin-1 in rheumatic diseases.
    Goldbach-Mansky R
    Ann N Y Acad Sci; 2009 Dec; 1182():111-23. PubMed ID: 20074280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Indications of anakinra].
    Chauffier K; London J; Beaudouin C; Fautrel B
    Presse Med; 2009 May; 38(5):799-807. PubMed ID: 19278814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Actual status of antiinterleukin-1 therapies in rheumatic diseases.
    Geyer M; Müller-Ladner U
    Curr Opin Rheumatol; 2010 May; 22(3):246-51. PubMed ID: 20150813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis.
    Cohen SB
    Rheum Dis Clin North Am; 2004 May; 30(2):365-80, vii. PubMed ID: 15172046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies.
    Cavalli G; Dinarello CA
    Rheumatology (Oxford); 2015 Dec; 54(12):2134-44. PubMed ID: 26209330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience.
    Zeft A; Hollister R; LaFleur B; Sampath P; Soep J; McNally B; Kunkel G; Schlesinger M; Bohnsack J
    J Clin Rheumatol; 2009 Jun; 15(4):161-4. PubMed ID: 19363453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-1: Ariadne's Thread in Autoinflammatory and Autoimmune Disorders.
    Cantarini L; Lopalco G; Cattalini M; Vitale A; Galeazzi M; Rigante D
    Isr Med Assoc J; 2015 Feb; 17(2):93-7. PubMed ID: 26223084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial response to anakinra and thalidomide in Schnitzler's syndrome.
    de Koning HD; Bodar EJ; Simon A; van der Hilst JC; Netea MG; van der Meer JW
    Ann Rheum Dis; 2006 Apr; 65(4):542-4. PubMed ID: 16096327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammasome and cytokine blocking strategies in autoinflammatory disorders.
    Moll M; Kuemmerle-Deschner JB
    Clin Immunol; 2013 Jun; 147(3):242-75. PubMed ID: 23697917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of extended treatment with anakinra in patients with rheumatoid arthritis.
    Fleischmann RM; Tesser J; Schiff MH; Schechtman J; Burmester GR; Bennett R; Modafferi D; Zhou L; Bell D; Appleton B
    Ann Rheum Dis; 2006 Aug; 65(8):1006-12. PubMed ID: 16396977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of tumour necrosis factor and interleukin-1 blocking agents in rheumatic diseases.
    Botsios C
    Autoimmun Rev; 2005 Mar; 4(3):162-70. PubMed ID: 15823502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of anakinra, a recombinant interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis and comparison to anti-TNF-alpha agents.
    Fleishmann RM
    Clin Exp Rheumatol; 2002; 20(5 Suppl 27):S35-41. PubMed ID: 14989428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-1 Inhibition in Behçet's disease.
    Vitale A; Rigante D; Lopalco G; Selmi C; Galeazzi M; Iannone F; Cantarini L
    Isr Med Assoc J; 2016; 18(3-4):171-6. PubMed ID: 27228638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What are the risks of biologic therapy in rheumatoid arthritis? An update on safety.
    Weisman MH
    J Rheumatol Suppl; 2002 Sep; 65():33-8. PubMed ID: 12236621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serious infections associated with anticytokine therapies in the rheumatic diseases.
    Giles JT; Bathon JM
    J Intensive Care Med; 2004; 19(6):320-34. PubMed ID: 15523118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France.
    Lequerré T; Quartier P; Rosellini D; Alaoui F; De Bandt M; Mejjad O; Kone-Paut I; Michel M; Dernis E; Khellaf M; Limal N; Job-Deslandre C; Fautrel B; Le Loët X; Sibilia J; ;
    Ann Rheum Dis; 2008 Mar; 67(3):302-8. PubMed ID: 17947302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Off-label use of anti-IL-1 drugs in rheumatic diseases.
    Stefania S; Colia R; Cinzia R; Corrado A; Cantatore FP
    Int J Immunopathol Pharmacol; 2021; 35():20587384211006584. PubMed ID: 33855881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome.
    Neven B; Marvillet I; Terrada C; Ferster A; Boddaert N; Couloignier V; Pinto G; Pagnier A; Bodemer C; Bodaghi B; Tardieu M; Prieur AM; Quartier P
    Arthritis Rheum; 2010 Jan; 62(1):258-67. PubMed ID: 20039428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.